# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: MRI and lumbar puncture results and the neurology consultation. **S**

## History of present illness

Ms. du Pré returns two weeks after her first visit. MRI of the brain and spine three days after that visit showed lesions typical of multiple sclerosis in the brain and the spinal cord, including an enhancing lesion at C3 to C4 that explains her hands, and the lumbar puncture a week ago showed oligoclonal bands in the spinal fluid only. Aquaporin-4 antibody was negative. She was seen today by Dr. Lindgren-Achebe. The numbness and clumsiness in her fingers are no better; she has practiced for only a few minutes at a time this week and has cancelled two more concerts. The electric feeling down her back when she bends her head continues. She is tired by mid-afternoon. She asked what multiple sclerosis will mean for her playing, and whether she can still have children. **S**

| Element | Detail |
|---|---|
| Diagnosis | Relapsing-remitting multiple sclerosis, active: dissemination in space and time on MRI and CSF-specific oligoclonal bands |
| Tests since the first visit | MRI of the brain and cervical and thoracic spine with gadolinium; lumbar puncture; aquaporin-4 antibody; HIV and syphilis serology |
| Symptoms | Numb, clumsy fingers, worse on the left; Lhermitte's sign; fatigue |
| Her questions | Whether she will play again; whether she can have children; how treatment will fit around concerts and teaching |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired by mid-afternoon; no fever; weight steady |
| Neurological | Positive | Numbness and clumsiness of the fingers; Lhermitte's sign; no weakness of the legs, imbalance or visual change |
| Genitourinary | Negative | No urinary urgency or burning; last period three weeks ago |
| Eyes | Negative | No blurred vision or pain on moving the eyes |
| Musculoskeletal | Negative | No back pain |
| Psychiatric | Positive | Frightened and tearful about her playing; PHQ-9 7, GAD-7 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 63.4 kg; BMI 21.2 kg/m². All vital signs are synthetic.

25-hydroxyvitamin D: 16 ng/mL (low); IgG: 1080 mg/dL; IgM: 124 mg/dL; PHQ-9: 7; GAD-7: 6; Nine-hole peg test, right hand: 24.5 s; Nine-hole peg test, left hand: 31 s. All results are synthetic.

## Change since baseline

- Nine-hole peg test, right hand: 26 s at baseline, 24.5 s at this visit **S**
- Nine-hole peg test, left hand: 33.5 s at baseline, 31 s at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine (PCV20), before B-cell therapy **S**
- Recombinant zoster vaccine, dose 1 of 2, before B-cell therapy **S**
- Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapy **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 63.4 kg; blood pressure 114/72, pulse 76 |
| Cranial nerves | Normal; no nystagmus; visual acuity and fields normal |
| Neurological | Reduced vibration and joint position sense in the fingers of both hands, worse on the left, with mild wandering of the left fingers when the eyes are closed; light touch reduced in the fingertips; finger and wrist strength 5 out of 5 except finger abduction 4+ on the left; brisk reflexes in the arms; Lhermitte's sign present; gait and balance normal. Nine-hole peg test 24.5 seconds right, 31.0 seconds left. EDSS 2.0 |
| Psychiatric | Warm and expressive; anxious; asks exact questions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing-remitting multiple sclerosis, active** (G35.A). Multiple sclerosis by the 2017 McDonald criteria: a current attack (partial cervical myelitis) with an earlier sensory episode in the history, dissemination in space (periventricular, juxtacortical, infratentorial and spinal cord lesions) and in time (enhancing and non-enhancing lesions together), with CSF-specific oligoclonal bands. The 2024 revision is also met, and most lesions show a central vein. Mimics were excluded: vitamin B12 and TSH were normal, aquaporin-4 antibody was negative, and HIV and syphilis serology were negative. MOG antibody was not tested, because nothing suggests MOG antibody disease (no optic neuritis, no long cord lesion, no ADEM-like picture). The relapse limits her hand function and her work, so high-dose steroids are offered. With active disease at 28, Dr. Lindgren-Achebe and she chose early high-efficacy therapy: ocrelizumab, over natalizumab because her JCV antibody is positive (index 1.4) with a higher risk of PML after two years, and over ofatumumab because she prefers two infusions a year to monthly injections when she travels. **S**
   - Methylprednisolone 1 g intravenously daily for 3 days from tomorrow; urine dipstick negative today.
   - Ocrelizumab 300 mg on day 1 in three weeks and on day 15, then 600 mg every six months.
   - PCV20, recombinant zoster dose 1 and hepatitis B dose 1 today, at least two weeks before the first infusion.
   - Occupational therapy for hand function and fatigue next week; MS specialist nurse contact.
2. **Vitamin D deficiency** (E55.9). 25-hydroxyvitamin D 16 ng/mL. Replaced to correct the deficiency; it is not a treatment for multiple sclerosis. **S**
   - Cholecalciferol 4000 units daily.
   - Level in about three months.
3. **Numbness and clumsiness of the hands with Lhermitte's sign** (R20.2). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | MRI of the brain and cervical and thoracic spine with gadolinium | At diagnosis | Up to date | Eleven typical brain lesions in periventricular, juxtacortical and infratentorial sites, one enhancing; enhancing C3 to C4 lesion and non-enhancing T7 lesion; central veins in most lesions |
| Laboratory | Cerebrospinal fluid: oligoclonal bands, cell count, protein | At diagnosis when it adds certainty | Up to date | Six CSF-specific oligoclonal bands; IgG index 0.86; white cells 6, protein 42 mg/dL |
| Laboratory | Mimics: vitamin B12, TSH, HIV, syphilis | At diagnosis | Up to date | B12 468 pg/mL and TSH 1.6 mIU/L at the first visit; HIV and syphilis negative |
| Laboratory | Aquaporin-4 antibody (cell-based assay) | When a myelitis or optic neuritis raises neuromyelitis optica spectrum disorder | Up to date | Negative |
| Laboratory | MOG antibody | Only when the picture suggests MOG antibody disease | Not indicated | No optic neuritis, long cord lesion or ADEM-like picture; typical MS lesions with central veins |
| Laboratory | JCV antibody | Before choosing natalizumab, and every six months while on it | Up to date | Positive, index 1.4 (drawn with the lumbar puncture); natalizumab not chosen |
| Laboratory | Hepatitis B (surface antigen, core antibody, surface antibody), varicella and measles immunity | Before anti-CD20 therapy | Up to date | Drawn with the lumbar puncture: hepatitis B surface antigen and core antibody negative, surface antibody negative (not immune); varicella IgG positive; measles immune by two recorded doses |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 1080 mg/dL, IgM 124 mg/dL |
| Laboratory | 25-hydroxyvitamin D | At diagnosis | Completed today | 16 ng/mL: deficient |
| Laboratory | Pregnancy test | Before steroids and before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Medication safety | Infection screen before high-dose steroids | Before each steroid course | Completed today | Urine dipstick negative; no fever |
| Medication safety | Vaccinations before B-cell therapy | Inactivated vaccines at least two weeks before the first dose; live vaccines at least four weeks before | Completed today | PCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; no live vaccine needed |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 24.5 seconds right, 31.0 seconds left (typical for her age about 17 to 19 seconds) |
| Examination | Neurological examination and EDSS | At diagnosis and at each review | Completed today | Sensory loss in the fingers, mild left finger weakness, Lhermitte's sign; EDSS 2.0 |
| Referral | Occupational therapy | For any problem with hand function or fatigue | Referred | Assessment booked for next week |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 7 (item 9 scored 0), GAD-7 6 |
| Self-management | Pregnancy planning and contraception | At diagnosis and at each review | Completed today | Pregnancy is possible with multiple sclerosis; on ocrelizumab, conception is best planned a few months after a dose, with the neurologist; condoms for now |
| Self-management | Written information and MS specialist nurse | At diagnosis | Completed today | Written information given; nurse contact and relapse line |

## Goal progress

- MRI of the brain and spine within one week and a neurology diagnosis within three weeks. Outcome by 2026-03-23: MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks. **S**
- High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations. In progress; target 2026-04-27. **S**
- Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed. In progress; target 2026-07-13. **S**
- No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression). In progress; target 2026-10-12. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more. In progress; target 2026-07-13. **S**
- PHQ-9 below 10 throughout. In progress; target 2026-10-12. **S**

## Medication changes

- Started: Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**

## Guideline basis

- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018), American Academy of Neurology
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018), European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
- Multiple sclerosis in adults: management (NICE guideline NG220) (2022), National Institute for Health and Care Excellence
- Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977) (2017), The Lancet Neurology
- Montalban X, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-865 (doi:10.1016/S1474-4422(25)00270-4) (2025), The Lancet Neurology
- Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021), The Lancet Neurology
- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology

## Follow-up

- Methylprednisolone from tomorrow for 3 days; occupational therapy next week; ocrelizumab day 1 in three weeks. Review at the second half-dose. Call at once for new weakness, imbalance, loss of vision or bladder control. **S**
- Next scheduled visit 2026-04-27: second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work. **S**
